These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6879128)

  • 21. Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer.
    Görlich M; Jandrig B
    J Exp Clin Cancer Res; 1997 Mar; 16(1):95-103. PubMed ID: 9148869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug therapy of breast carcinoma].
    Dittrich C
    Wien Med Wochenschr; 2000; 150(4):72-86. PubMed ID: 10829307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Estrogen receptors and the mammary gland].
    Barrón A; Bermejo L; Castro I
    Rev Invest Clin; 1997; 49(6):515-28. PubMed ID: 9528313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A predictive model for the development of hormone-responsive breast cancer.
    Gorla SR; Hou N; Acharya S; Rademaker A; Khan S; Staradub V; Morrow M
    Ann Surg Oncol; 2005 Jan; 12(1):48-56. PubMed ID: 15827778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
    Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
    Moy B; Goss PE
    Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reliability of estrogen receptors in predicting response to antiestrogens.
    Valavaara R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hormone therapy of metastasizing breast carcinoma].
    Hagen MF; Thürlimann B
    Ther Umsch; 1996 Nov; 53(11):820-8. PubMed ID: 8984687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials update: Medical management of advanced breast cancer.
    Major MA
    Cancer Nurs; 2003 Dec; 26(6 Suppl):10S-15S. PubMed ID: 15025407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
    Manders P; Beex LV; Tjan-Heijnen VC; Span PN; Sweep CG
    Cancer; 2003 Nov; 98(10):2125-32. PubMed ID: 14601081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of response to systemic therapy in breast cancer.
    Ring AE; Ellis PA
    Forum (Genova); 2002; 12(1):19-32. PubMed ID: 12634908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutics: hormone therapy for breast cancer].
    Wehrlin N
    Rev Infirm; 1983 Jun; 33(11):35-8. PubMed ID: 6553966
    [No Abstract]   [Full Text] [Related]  

  • 38. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor protein and its correlation to recurrent breast cancer. A study of 213 patients at the Pennsylvania Hospital.
    Lerner HJ; Marcovitz E
    Cancer Clin Trials; 1981; 4(1):17-9. PubMed ID: 7214659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.